newsfilter.io

Noubar Afeyan

Showing 11 of 1 transcripts.

  1. Milken Institute1h 1m

    Where Is the Next Cure? | Global Conference 2024

    Alice Park, Noubar Afeyan, Aloe Blacc, Daphne Koller, Samarth Kulkarni, Pablo Legorreta

    Leading biotech executives and researchers are redefining the industry by shifting from chronic small-molecule management to precise, curative systems-based therapies like CRISPR and mRNA platforms. This transition, fueled by artificial intelligence and a "reverse translation" innovation model, has accelerated clinical timelines while projecting a $100 billion market for GLP-1 drugs and new organ-editing solutions. Despite regulatory hurdles and high initial costs for treatments like sickle cell gene editing, stakeholders anticipate that maturing technologies and scalable manufacturing will eventually democratize access to these transformative medical breakthroughs.